Quarterly ResultMay 14, 2026, 04:39 PM
BioRestorative Therapies Q1 Net Loss Narrows to $2.15M; Raises $4.4M
AI Summary
BioRestorative Therapies reported a reduced net loss of $2.15 million for Q1 2026, an improvement from $5.34 million in Q1 2025, with net loss per share improving to $(0.12). The company significantly bolstered its liquidity by raising $4.4 million in net proceeds from a public offering, increasing cash and cash equivalents to $3.11 million and reducing total current liabilities. However, the company received a Nasdaq notice for non-compliance with the minimum bid price requirement and management expressed substantial doubt about its ability to continue as a going concern.
Key Highlights
- Q1 2026 net loss narrowed to $2.15 million from $5.34 million in Q1 2025.
- Net loss per share improved to $(0.12) from $(0.64) year-over-year.
- Received net proceeds of $4.4 million from a public offering of common stock and warrants.
- Cash and cash equivalents increased to $3.11 million as of March 31, 2026.
- Total current liabilities decreased to $1.61 million from $3.72 million since Dec 31, 2025.
- Recognized a $1.22 million gain from the change in fair value of warrant liabilities.
- Received Nasdaq notice for non-compliance with the $1.00 minimum bid price rule.
- Management noted substantial doubt about the company's ability to continue as a going concern.